1126 - 1150 of 7939 Results
Title
Year
- Proximity to residential and workplace pesticides application and the risk of progression of Parkinson's diseases in Central California2022OPENTitle: Proximity to residential and workplace pesticides application and the risk of progression of Parkinson's diseases in Central CaliforniaJournal Name: Science of The Total EnvironmentPublisher: Elsevier BVVol: 864Issue #:Start Page: 160851End Page: 160851Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.scitotenv.2022.160851Best OA location URL: https://doi.org/10.1016/j.scitotenv.2022.160851Citation Count: 17
-
OPENTitle: Nomogram to Predict the Probability of Functional Dependence in Early Parkinson’s DiseaseJournal Name: Journal of Parkinson's DiseasePublisher: SAGE PublicationsVol: 13Issue #: 1Start Page: 49End Page: 55Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3233/jpd-223501Best OA location URL: https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd223501?id=journal-of-parkinsons-disease%2Fjpd223501Citation Count: 3
- Predicting longitudinal brain atrophy in Parkinson’s disease using a Susceptible-Infected-Removed agent-based model2022OPENTitle: Predicting longitudinal brain atrophy in Parkinson’s disease using a Susceptible-Infected-Removed agent-based modelJournal Name: Network NeurosciencePublisher: MIT PressVol: 7Issue #: 3Start Page: 906End Page: 925Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1162/netn_a_00296Best OA location URL: https://direct.mit.edu/netn/article-pdf/doi/10.1162/netn_a_00296/2074404/netn_a_00296.pdfCitation Count: 7
- Association of Sodium–Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study2022OPENTitle: Association of Sodium–Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort StudyJournal Name: Diabetes CarePublisher: American Diabetes AssociationVol: 46Issue #: 2Start Page: 297End Page: 304Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.2337/dc22-1705Best OA location URL: https://diabetesjournals.figshare.com/articles/figure/Association_of_sodium-glucose_cotransporter-2_inhibitors_with_time_to_dementia_a_population-based_cohort_study/21445284/1/files/38063811.pdfCitation Count: 43
-
OPENTitle: Isolated Jaw and Tongue Tremor in a Definite Case of Progressive Supranuclear PalsyJournal Name: Movement Disorders Clinical PracticePublisher: WileyVol: 10Issue #: 2Start Page: 348End Page: 349Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mdc3.13640Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mdc3.13640Citation Count: 0
-
RESTRICTEDTitle: LRRK2-targeted Parkinson disease drug advances into phase IIIJournal Name: Nature Reviews Drug DiscoveryPublisher: Springer Science and Business Media LLCVol: 22Issue #: 1Start Page: 3End Page: 5Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1038/d41573-022-00212-0Citation Count: 8
- Predictive modelling of Parkinson’s disease progression based on RNA-Sequence with densely connected deep recurrent neural networks2022OPENTitle: Predictive modelling of Parkinson’s disease progression based on RNA-Sequence with densely connected deep recurrent neural networksJournal Name: Scientific ReportsPublisher: Springer Science and Business Media LLCVol: 12Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1038/s41598-022-25454-1Best OA location URL: https://www.nature.com/articles/s41598-022-25454-1.pdfCitation Count: 3
-
OPENTitle: The genetic regulation of protein expression in cerebrospinal fluidJournal Name: EMBO Molecular MedicinePublisher: Springer Science and Business Media LLCVol: 15Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.15252/emmm.202216359Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.15252/emmm.202216359Citation Count: 21
- Video-Based Facial Movement Analysis in the Assessment of Bulbar Amyotrophic Lateral Sclerosis: Clinical Validation2022OPENTitle: Video-Based Facial Movement Analysis in the Assessment of Bulbar Amyotrophic Lateral Sclerosis: Clinical ValidationJournal Name: Journal of Speech, Language, and Hearing ResearchPublisher: American Speech Language Hearing AssociationVol: 65Issue #: 12Start Page: 4667End Page: 4678Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1044/2022_jslhr-22-00072Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940890Citation Count: 11
- Chemosensory Dysfunction 3-Months After COVID-19, Medications and Factors Associated with Complete Recovery2022OPENTitle: Chemosensory Dysfunction 3-Months After COVID-19, Medications and Factors Associated with Complete RecoveryJournal Name: Annals of Otology, Rhinology & LaryngologyPublisher: SAGE PublicationsVol: 132Issue #: 10Start Page: 1177End Page: 1185Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1177/00034894221138485Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742352Citation Count: 2
- It Is as It Was: MDS‐UPDRS Part III Scores Cannot Be Combined with Other Parts to Give a Valid Sum2022OPENTitle: It Is as It Was: MDS‐UPDRS Part III Scores Cannot Be Combined with Other Parts to Give a Valid SumJournal Name: Movement DisordersPublisher: WileyVol: 38Issue #: 2Start Page: 342End Page: 347Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.29279Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974855Citation Count: 9
-
OPENTitle: Tailoring Motor Fluctuation Treatment: Beyond Levodopa Dose AdjustmentJournal Name: European Medical JournalPublisher: European Medical GroupVol:Issue #:Start Page: 20End Page: 27Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.33590/emj/10022165Best OA location URL: https://www.emjreviews.com/wp-content/uploads/2022/12/Tailoring-Motor-Fluctuation-Treatment-Beyond-Levodopa-Dose-Adjustment-1.pdfCitation Count: 0
- Brain vitamin D forms, cognitive decline, and neuropathology in community‐dwelling older adults2022OPENTitle: Brain vitamin D forms, cognitive decline, and neuropathology in community‐dwelling older adultsJournal Name: Alzheimer's & DementiaPublisher: WileyVol: 19Issue #: 6Start Page: 2389End Page: 2396Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1002/alz.12836Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/alz.12836Citation Count: 14
- Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1H-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson’s Disease2022RESTRICTEDTitle: Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1H-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson’s DiseaseJournal Name: Journal of Medicinal ChemistryPublisher: American Chemical Society (ACS)Vol: 65Issue #: 24Start Page: 16801End Page: 16817Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1021/acs.jmedchem.2c01605Citation Count: 10
-
OPENTitle: Spectrum of Pediatric to Early Adulthood POLR3A‐Associated Movement DisordersJournal Name: Movement Disorders Clinical PracticePublisher: WileyVol: 10Issue #: 2Start Page: 316End Page: 322Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mdc3.13635Citation Count: 2
-
OPENTitle: A Severe Case of Lupus CerebritisJournal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 99Issue #: 23_Supplement_2Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1212/01.wnl.0000903100.95793.8aBest OA location URL: https://n.neurology.org/content/neurology/99/23_Supplement_2/S9.full.pdfCitation Count: 1
- An Observational Study on the Humoral and Cellular Immune Response to SARS-CoV-2 mRNA Vaccination in Multiple Sclerosis and Other Autoimmune Neurological Disorders Treated With Anti-CD20 Therapies2022OPENTitle: An Observational Study on the Humoral and Cellular Immune Response to SARS-CoV-2 mRNA Vaccination in Multiple Sclerosis and Other Autoimmune Neurological Disorders Treated With Anti-CD20 TherapiesJournal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 99Issue #: 23_Supplement_2Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1212/01.wnl.0000903428.98962.0aBest OA location URL: https://n.neurology.org/content/neurology/99/23_Supplement_2/S52.full.pdfCitation Count: 0
- Brain and Cerebrospinal Fluid α‐Synuclein Real‐Time Quaking‐Induced Conversion Identifies Lewy Body Pathology in LRRK2‐PD2022OPENTitle: Brain and Cerebrospinal Fluid α‐Synuclein Real‐Time Quaking‐Induced Conversion Identifies Lewy Body Pathology in LRRK2‐PDJournal Name: Movement DisordersPublisher: WileyVol: 38Issue #: 2Start Page: 333End Page: 338Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1002/mds.29284Best OA location URL: https://doi.org/10.1002/mds.29284Citation Count: 15
- Examining the Differences in Biomarkers of Neuronal and Glial Injury Between Autoimmune Neurologic Disease Patients and Healthy Controls2022OPENTitle: Examining the Differences in Biomarkers of Neuronal and Glial Injury Between Autoimmune Neurologic Disease Patients and Healthy ControlsJournal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 99Issue #: 23_Supplement_2Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1212/01.wnl.0000903096.36040.1dBest OA location URL: https://n.neurology.org/content/neurology/99/23_Supplement_2/S8.full.pdfCitation Count: 0
- Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effects2022OPENTitle: Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effectsJournal Name: Nature CommunicationsPublisher: Springer Science and Business Media LLCVol: 13Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.1038/s41467-022-34732-5Best OA location URL: https://www.nature.com/articles/s41467-022-34732-5.pdfCitation Count: 30
- Protective Association of HLA-DRB1*04 Subtypes in Neurodegenerative Diseases Implicates Acetylated Tau PHF6 Sequences2022OPENTitle: Protective Association of HLA-DRB1*04 Subtypes in Neurodegenerative Diseases Implicates Acetylated Tau PHF6 SequencesJournal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 99Issue #: 23_Supplement_2Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1212/01.wnl.0000903160.72715.2dBest OA location URL: https://n.neurology.org/content/neurology/99/23_Supplement_2/S17.1.full.pdfCitation Count: 1
- Safety, Efficacy, And Pharmacokinetics of Argx-117 in Adults With Multifocal Motor Neuropathy: A Global, Multicenter, Placebo Controlled Phase 2 Study (Arda)2022OPENTitle: Safety, Efficacy, And Pharmacokinetics of Argx-117 in Adults With Multifocal Motor Neuropathy: A Global, Multicenter, Placebo Controlled Phase 2 Study (Arda)Journal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 99Issue #: 23_Supplement_2Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1212/01.wnl.0000903320.23411.f9Best OA location URL: https://n.neurology.org/content/neurology/99/23_Supplement_2/S40.full.pdfCitation Count: 1
-
OPENTitle: Substitution of PINK1 Gly411 modulates substrate receptivity and turnoverJournal Name: AutophagyPublisher: Informa UK LimitedVol: 19Issue #: 6Start Page: 1711End Page: 1732Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1080/15548627.2022.2151294Best OA location URL: https://doi.org/10.1080/15548627.2022.2151294Citation Count: 11
- The ExTINGUISH Trial: A Phase-2B Randomized Placebo-Controlled Trial of Inebilizumab in Anti-NMDA Receptor Encephalitis2022OPENTitle: The ExTINGUISH Trial: A Phase-2B Randomized Placebo-Controlled Trial of Inebilizumab in Anti-NMDA Receptor EncephalitisJournal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 99Issue #: 23_Supplement_2Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1212/01.wnl.0000903316.50895.83Best OA location URL: https://n.neurology.org/content/neurology/99/23_Supplement_2/S39.full.pdfCitation Count: 2
- Understanding Correlation of Electroclinical Findings With Functional and Neuropsychiatric Outcomes in Patients with LGI1-Encephalitis2022RESTRICTEDTitle: Understanding Correlation of Electroclinical Findings With Functional and Neuropsychiatric Outcomes in Patients with LGI1-EncephalitisJournal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 99Issue #: 23_Supplement_2Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1212/01.wnl.0000903424.19914.85Citation Count: 0